Along with the rest of the market, Novo Nordisk (NYSE:NVO) has been sinking this year – with losses approaching 30% ...

In a report released on April 22, David Evans from Kepler Capital maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a ...

Shares in Novo Nordisk were up nearly 12% today – hiking its valuation to more than $280 billion – after it reported new clinical data with one of its obesity drug candidates. The new results ...

Novo Nordisk’s UK unit has been suspended as a member of the Association of the British Pharmaceutical Industry (ABPI) for two years due to what was described as “serious breaches” of the ...